Cmp Patent-Cliff Exposure & CMS Drug Spending Portfolio
Cmp (US): 5 reconciled FDA prescription therapies, $16.3M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2038-01-01 |
| 2024 CMS Total Public Spend | $16.3M |
| 2024 Medicare Part D Spend | $13.7M |
| 2024 Medicaid Spend | $2.6M |
| California HCAI SB 17 Filings | 3 WAC filings (max 185.5% 2-yr change) |